Intellia Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Intellia Therapeutics, Inc. (NTLA) holds an ST Score of 47.3 out of 100 (C+), with its strongest factor being Forecast (A-) and its weakest Growth (C). Analysts rate NTLA Buy across 39 ratings with a $23.00 average price target (+0.9% vs the current $12.22).
- Strongest
- ForecastA-
- Weakest
- GrowthC
All factor grades
- ForecastA-
- ValuationB-
- ProfitabilityC+
- SentimentC+
- Financial StrengthC
- MomentumC
- GrowthC
- Piotroski3/9
Contact
NTLA stock: frequently asked questions
What is NTLA's ST Score?
Intellia Therapeutics, Inc. (NTLA) has an ST Score of 47.3 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NTLA a buy, sell, or hold?
Wall Street's consensus rating on NTLA is Buy based on 39 analyst ratings. Our own ST Score grades it C+ (47.3/100). This is data, not investment advice — always do your own research.
What is NTLA's valuation grade?
Intellia Therapeutics, Inc. (NTLA) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NTLA's growth grade?
Intellia Therapeutics, Inc. (NTLA) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NTLA's profitability grade?
Intellia Therapeutics, Inc. (NTLA) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NTLA's financial strength grade?
Intellia Therapeutics, Inc. (NTLA) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NTLA?
The average analyst price target for Intellia Therapeutics, Inc. (NTLA) is $23.00 from 39 analysts, which is +0.9% versus the recent price of $12.22.
What is NTLA's Piotroski score?
Intellia Therapeutics, Inc. (NTLA) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.